Related references
Note: Only part of the references are listed.Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma
Inan Olmez et al.
CANCER RESEARCH (2018)
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
Mohamed Bouattour et al.
HEPATOLOGY (2018)
The implications of TrkA and MET aberrations in de novo salivary duct carcinoma
Hyang Joo Ryu et al.
HUMAN PATHOLOGY (2018)
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
Bruce W. Konicek et al.
Oncotarget (2018)
Inhibiting TRK Proteins in Clinical Cancer Therapy
Allison M. Lange et al.
CANCERS (2018)
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Miho J. Fuse et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling
Eunice Yuen Ting Lau et al.
CELL REPORTS (2016)
Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future Directions
Kyung-Ju Choi et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
A novel mechanism of hepatocellular carcinoma cell apoptosis induced by lupeol via Brain-Derived Neurotrophic Factor Inhibition and Glycogen Synthase Kinase 3 beta reactivation
Lingli Zhang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
Giuditta Viticchie et al.
BIOMEDICINES (2015)
Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Qingfeng Xiang et al.
CLINICAL CANCER RESEARCH (2014)
Precision therapy for lymphoma-current state and future directions
Andrew M. Intlekofer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
Angela Gauthier et al.
HEPATOLOGY RESEARCH (2013)
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva et al.
CLINICAL CANCER RESEARCH (2012)
Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models
Pam Albaugh et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
DNA methylation-dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma
Wook Jin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy
Soohyeon Lee et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells
Dawei Guo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor-Dependent Fashion to Suppress Carcinoma Growth
Yu-Wen Zhang et al.
CANCER RESEARCH (2010)
Targeting the HGF/Met signalling pathway in cancer
Fabiola Cecchi et al.
EUROPEAN JOURNAL OF CANCER (2010)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
Crosstalk in Met receptor oncogenesis
Andrea Z. Lai et al.
TRENDS IN CELL BIOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416
C Ye et al.
TOXICOLOGY IN VITRO (2006)
The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness
M Hecht et al.
CARCINOGENESIS (2005)
Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo
SZ Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activation of the c-Met receptor complex in fibroblasts drives invasive cell behavior by signaling through transcription factor STAT3
A Cramer et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells
SY Wang et al.
JOURNAL OF HEPATOLOGY (2004)
K252a inhibits the oncogenic properties of Met, the HGF receptor
A Morotti et al.
ONCOGENE (2002)
Production of nerve growth factor by mouse hepatocellular carcinoma cells and expression of TrkA in tumor-associated arteries in mice
K Kishibe et al.
GASTROENTEROLOGY (2002)
Trk receptor tyrosine kinases: A bridge between cancer and neural development
A Nakagawara
CANCER LETTERS (2001)
Share Paper
